Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

94 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The World Health Organization Pandemic Agreement draft: Considerations by the ESCMID Emerging Infections Task Force (EITaF).
Granata G, Astorri R, Broens EM, Callaby H, Cunha F, Di Caro A, Fusco FM, Greub G, Grobusch MP, Koopmans M, Pereira do Vale A, Pisapia R, Rovers CP, Tostmann A, Tunali V, de Valdoleiros SR, Petersen E. Granata G, et al. Among authors: fusco fm. Clin Microbiol Infect. 2024 May 29:S1198-743X(24)00253-2. doi: 10.1016/j.cmi.2024.05.016. Online ahead of print. Clin Microbiol Infect. 2024. PMID: 38821176 No abstract available.
Implications of the 2023-2024 MPXV clade I outbreak in the Democratic Republic of Congo to global public health.
Desai AN, Koopmans M, Otter A, Grobusch MP, Jokelainen P, Atkinson B, Cunha F, Valdoleiros SR, Preda VG, Fusco FM, Rovers CP, Greub G, Di Caro A, Simonsen L, Ntoumi F, Petersen E. Desai AN, et al. Among authors: fusco fm. Clin Microbiol Infect. 2024 Apr 30:S1198-743X(24)00213-1. doi: 10.1016/j.cmi.2024.04.016. Online ahead of print. Clin Microbiol Infect. 2024. PMID: 38697394 No abstract available.
Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort.
d'Arminio Monforte A, Tavelli A, Di Biagio A, Sarmati L, Marchetti GC, Bai F, Cingolani A, Quiros Roldan E, Mussini C, Lichtner M, Vergori A, Piconi S, Orofino G, Fusco FM, Bandera A, Nozza S, Castagna A, Antinori A; ICONA Foundation Study Group. d'Arminio Monforte A, et al. Among authors: fusco fm. J Antimicrob Chemother. 2024 Jun 3;79(6):1279-1288. doi: 10.1093/jac/dkae081. J Antimicrob Chemother. 2024. PMID: 38581349
Predictors of Mortality and Orotracheal Intubation in Patients with Pulmonary Barotrauma Due to COVID-19: An Italian Multicenter Observational Study during Two Years of the Pandemic.
Tetaj N, De Pascale G, Antonelli M, Vargas J, Savino M, Pugliese F, Alessandri F, Giordano G, Tozzi P, Rocco M, Biava AM, Maggi L, Pisapia R, Fusco FM, Stazi GV, Garotto G, Marini MC, Piselli P, Beccacece A, Mariano A, Giancola ML, Ianniello S, Vaia F, Girardi E, Antinori A, Bocci MG, Marchioni L, Nicastri E; PTX/PNM Study Group. Tetaj N, et al. Among authors: fusco fm. J Clin Med. 2024 Mar 15;13(6):1707. doi: 10.3390/jcm13061707. J Clin Med. 2024. PMID: 38541932 Free PMC article.
Determinants of worse liver-related outcome according to HDV infection among HBsAg positive persons living with HIV: Data from the ICONA cohort.
d'Arminio Monforte A, Tavelli A, Salpini R, Piermatteo L, D'Anna S, Carrara S, Malagnino V, Mazzotta V, Brancaccio G, Marchetti GC, Rosselli Del Turco E, Rossotti R, Mussini C, Antinori A, Lo Caputo S, Ceccherini Silberstein F, Gaeta GB, Svicher V, Puoti M; Icona Foundation Study Group. d'Arminio Monforte A, et al. Liver Int. 2024 Feb;44(2):603-613. doi: 10.1111/liv.15804. Epub 2023 Dec 15. Liver Int. 2024. PMID: 38100128 Free article.
Risk of COVID-19 in-hospital mortality in people living with HIV compared to general population according to age and CD4 strata: data from the ICONA network.
Giacomelli A, Gagliardini R, Tavelli A, De Benedittis S, Mazzotta V, Rizzardini G, Mondi A, Augello M, Antinori S, Vergori A, Gori A, Menozzi M, Taramasso L, Fusco FM, De Vito A, Mancarella G, Marchetti G, D'Arminio Monforte A, Antinori A, Cozzi-Lepri A; COVID-19 ICONA study group. Giacomelli A, et al. Among authors: fusco fm. Int J Infect Dis. 2023 Nov;136:127-135. doi: 10.1016/j.ijid.2023.09.015. Epub 2023 Sep 22. Int J Infect Dis. 2023. PMID: 37741311 Free article.
Clinical and epidemiological factors causing longer SARS-CoV 2 viral shedding: the results from the CoviCamp cohort.
Grimaldi P, Russo A, Pisaturo M, Maggi P, Allegorico E, Gentile I, Sangiovanni V, Rossomando A, Pacilio R, Calabria G, Pisapia R, Carriero C, Masullo A, Manzillo E, Russo G, Parrella R, Dell'Aquila G, Gambardella M, Ponticiello A, Onorato L, Coppola N; CoviCam group. Grimaldi P, et al. Infection. 2024 Apr;52(2):439-446. doi: 10.1007/s15010-023-02095-8. Epub 2023 Sep 13. Infection. 2024. PMID: 37704910 Free PMC article.
Is HCV elimination among persons living with HIV feasible? Data from the NoCo study in the setting of the ICONA cohort.
d'Arminio Monforte A, Tavelli A, Rossotti R, Gagliardini R, Saracino A, Lo Caputo S, Sala M, Quiros-Roldan E, Mussini C, Girardi E, Cozzi-Lepri A, Antinori A, Puoti M; NoCo Study of the Icona cohort. d'Arminio Monforte A, et al. Liver Int. 2023 Oct;43(10):2130-2141. doi: 10.1111/liv.15700. Epub 2023 Aug 31. Liver Int. 2023. PMID: 37649460 Free article.
Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir.
González-Cordón A, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, Fox J, Stellbrink HJ, Guaraldi G, Masiá M, Gompels M, De Wit S, Florence E, Esser S, Raffi F, Behrens G, Pozniak A, Gatell JM, Martínez E; NEAT 022 Study Group. González-Cordón A, et al. J Antimicrob Chemother. 2023 Sep 5;78(9):2361-2365. doi: 10.1093/jac/dkad247. J Antimicrob Chemother. 2023. PMID: 37539492
94 results